Otsuka Beijing Research Institute
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2003-08-29
- Employees
- -
- Market Cap
- -
- Website
- http://www.obri.com.cn
Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT01359462
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 535
- Registration Number
- NCT01349348
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 180
- Registration Number
- NCT01349335
- Locations
- 🇨🇳
Renji hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 264
- Registration Number
- NCT01349010
- Locations
- 🇨🇳
The Sencond Xiangya Hospital of Central South University, Changsha, Hunan, China
A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
- Conditions
- Diabetic Nephropathy
- Interventions
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 353
- Registration Number
- NCT01252056
- Locations
- 🇨🇳
Beijing Universuty First Hospital, Beijng, Beijing, China
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 51
- Registration Number
- NCT01184807
- Locations
- 🇸🇬
National University Hospital (s) PTE LTD., Singapore, Singapore
🇸🇬National Cancer Centre, Department of Medical Oncology, Singapore, Singapore
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
- Conditions
- Type 2 Diabetes MellitusArteriosclerosis Obliterans
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT00823849
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject
- Conditions
- Atherosclerosis Cerebral Infarction
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT00823875
- Locations
- 🇨🇳
First Affliate Hospital of Beijing University, Beijing, China
A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients with Non-hypovolemic Non-acute Hyponatremia
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 241
- Registration Number
- NCT00664014
- Locations
- 🇨🇳
Endocrinology, No. 301 hospital, Beijing, China
🇨🇳Hepatology, Beijing Renmin Hospital, Beijing, China
🇨🇳Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00511082
- Locations
- ðŸ‡ðŸ‡°
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong